Antioxidant News and Research

RSS

Antioxidants are substances that protect cells from the damage caused by free radicals (unstable molecules made by the process of oxidation during normal metabolism). Free radicals may play a part in cancer, heart disease, stroke, and other diseases of aging. Antioxidants include beta-carotene, lycopene, vitamins A, C, and E, and other natural and manufactured substances.

Researchers test Orizon Research's ALKA-V6 silicon-based compound

Researchers at Texas State University-San Marcos have completed initial testing of a cancer chemotherapeutic and anti-retroviral compound with promising results.

14 Oct 2009

Parkinson's patients with higher urate levels in their blood and CSF had slower functional decline

Individuals with Parkinson's disease who have higher levels of a metabolite called urate in their blood and in cerebrospinal fluid (CSF) have a slower rate of disease progression, according to a study funded by the National Institutes of Health.

14 Oct 2009

Synta Pharmaceuticals updates its Phase 3 SYMMETRY trial results at the Melanoma XIII Conference

Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that additional results from its Phase 3 trial (SYMMETRYSM) of elesclomol in combination with paclitaxel in metastatic melanoma was presented at the Perspectives in Melanoma XIII Conference by Steven O’Day, M.D., principal investigator and Chief of Research and Director of the Melanoma Program at the Angeles Clinic in Santa Monica, California.

12 Oct 2009

Results of Phase 2a clinical trial of DR Cysteamine announced by Raptor Pharmaceutical

Raptor Pharmaceutical Corp., announced positive findings from the completed treatment phase of its open-label Phase 2a clinical trial of delayed-release cysteamine bitartrate ("DR Cysteamine") in adolescent patients with non-alcoholic steatohepatitis ("NASH"), a progressive form of liver disease believed to affect 2% to 5% of the U.S. population.

12 Oct 2009

First-quarter fiscal 2010 results announced by Biomet

Biomet, Inc. announced today financial results for its first fiscal quarter ended August 31, 2009.

9 Oct 2009

Valensa initiates licensing patent for the use of the astaxanthin as a dietary supplement

Valensa International (Orlando, FL USA) announced today that it has initiated a broad out licensing effort for University of Illinois patent (US 5,527,533 and its foreign equivalents) for the use of the astaxanthin in eye healthcare dietary supplement applications.

8 Oct 2009

Aeolus Pharmaceuticals’ AEOL 10150 effective against mustard gas exposure

Aeolus Pharmaceuticals, Inc. reported that researchers from National Jewish Health and Lovelace Respiratory Research Institute have completed a series of preliminary studies demonstrating that AEOL 10150 protects lungs from whole mustard gas exposure in rats. Data were presented at the Regional CounterACT Countermeasures Against Chemical Threats Conference in Albuquerque, NM.

8 Oct 2009

Low levels of ROS might protect us from diabetes, says study

We've all heard about the damage that reactive oxygen species (ROS) - aka free radicals - can do to our bodies and the sales pitches for antioxidant vitamins, skin creams or "superfoods" that can stop them. In fact, there is considerable scientific evidence that chronic ROS production within cells can contribute to human diseases, including insulin resistance and type 2 diabetes.

7 Oct 2009

New line of supplement products from Innovative Beverage Products

Amidst the cluttered counters within stores across the nation that contain countless copycat and unimaginative energy shots comes a new healthy twist and spark of vitality to the shot category. HealthShots(TM) - a new product line fortified with a host of healthy blends formulated specifically to taste great while also providing functional ingredients based on health and wellness concerns - has just launched in Long Island.

7 Oct 2009

Aeolus Pharmaceuticals raises $1.65 million from existing institutional shareholders

Aeolus Pharmaceuticals, Inc. announced today that it has completed a $1.65 million financing with several existing institutional shareholders, all of which are affiliates of Xmark Opportunity Partners, LLC. Under the terms of the financing, Aeolus received $1.65 million in gross proceeds in exchange for 5,892,857 Units (the “Units”), with each Unit comprised of one share of Aeolus Pharmaceuticals common stock, and a seven year warrant to purchase up to two additional shares of Aeolus Pharmaceuticals common stock at an initial exercise price of $0.28 per share, for a per Unit purchase price of $0.28.

7 Oct 2009

Eat strawberries to improve cholesterol levels

According to a new study published in the October 2009 issue of Nutrition Journal, women with metabolic syndrome had reduced total cholesterol levels - including LDL - after a brief period of daily consumption of a strawberry-based beverage.

6 Oct 2009

Levels of vitamin C higher in fruit juices than specified on labels

A team of pharmacists from the University of Santiago de Compostela (USC) has established that the levels of vitamin C in many fruit juices and soft drinks are far higher than those indicated on their labels by the manufacturers. This finding has been possible owing to a new technique developed by the researchers to determine the content of vitamin C in these kinds of drinks.

5 Oct 2009

CSPI sues Bayer for false claims on Men's One A Day multivitamins

The Center for Science in the Public Interest has sued the German drug company Bayer for falsely claiming that the selenium in Men's One A Day multivitamins might reduce the risk of prostate cancer. The lawsuit is filed in the Superior Court of California in San Francisco.

3 Oct 2009

UCF research team develops miniature diagnostic tool kit for dementia

With the risk of developing dementia growing at an alarming pace, a University of Central Florida research team is working with the Boston University School of Medicine to develop a miniature diagnostic toolkit in the hopes of stimulating earlier detection and treatment.

1 Oct 2009

Soybeans can prevent heart disease and cancer

Soybeans contain high levels of several health-beneficial compounds including tocopherols, which have antioxidant properties. These molecules can be used in the development of functional foods, which have specific health-beneficial properties and can be used in the treatment or prevention of diseases.

30 Sep 2009

Moderately elevated levels of ROS positive in fruit flies

It has been known for decades that reactive oxygen species (ROS) - ions or very small molecules that include free radicals - damage cells. But much to their surprise, Jonsson Cancer Center researchers found that in Drosophila, the common fruit fly, moderately elevated levels of ROS are a good thing.

25 Sep 2009

NIH awards $2.5 million grant to University of Utah cardiologist

A pioneering model that a University of Utah cardiologist proposes as a cause of heart disease is the kind of creative thinking the National Institutes of Health (NIH) likes to see-and reward with one of its most prestigious honors, a $2.5 million 2009 Pioneer Award.

24 Sep 2009

NBI Juiceworks increases distribution network in Texas

NBI Juiceworks has joined forces with two of the leading distributors in Texas: Metroplex Organics, based in the Dallas-Ft. Worth area and Houston-based Bev Source. Both companies will be distributing Drenchers(TM) 100 percent all natural super juices, Fit 'N Lean super juices and all natural Fit 'N Lean Super Blends.

24 Sep 2009

Organic revitalizing beverage from Sambazon

Sambazon, the global leader in Acai, announces the launch of a powerfully nutritious premium juice line. Antioxidant Elixir(TM) is a organic revitalizing beverage that provides powerful antioxidants and 600% DV Vitamin C, yet remains refreshingly light on calories, sugar, and contains no fat.

23 Sep 2009

Coenzyme Q10 to slow down the effects of Parkinson's disease?

Rush University Medical Center is participating in a large-scale, multi-center clinical trial in the U.S. and Canada to determine whether a vitamin-like substance, in high doses, can slow the progression of Parkinson's disease, a neurodegenerative disorder that affects about one million people in the United States.

22 Sep 2009